Maze Therapeutics, Inc. (MAZE) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "MAZE"
      ],
      "issuer_cik": "0001842295",
      "owner_cik": "0001676170",
      "accession_number": "0001676170-26-000024",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Maze Therapeutics, Inc.",
      "issuer_trading_symbol": "MAZE",
      "owner_name": "Coloma Jason V",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Executive Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 2593,
      "transaction_price_per_share": 27.0241,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 15558,
      "transaction_value": 70073.49130000001,
      "direct_or_indirect": "I",
      "nature_of_ownership": "The Coloma 2021 Irrevocable Trust",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."
        },
        {
          "id": "F2",
          "description": "The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.645 to $27.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4."
        },
        {
          "id": "F3",
          "description": "These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees."
        }
      ]
    },
    {
      "tickers": [
        "MAZE"
      ],
      "issuer_cik": "0001842295",
      "owner_cik": "0002050172",
      "accession_number": "0002050172-26-000038",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Maze Therapeutics, Inc.",
      "issuer_trading_symbol": "MAZE",
      "owner_name": "Bernstein Harold",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "President, R&D & CMO",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 16141,
      "transaction_price_per_share": 26.9341,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 0,
      "transaction_value": 434743.3081,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."
        },
        {
          "id": "F2",
          "description": "The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.